All In Biotech

Drug Trial Radar · NCT07384975

A Study to Assess NAV-240 in Adult Participants With Hidradenitis Suppurativa

A Phase 2a, Multicenter, Randomized, Double-blind, Placebo-controlled Study of NAV-240 in Adult Participants With Moderate-to-Severe Hidradenitis Suppurativa

Last checked: Nov 20, 2026Latest source record: Jul 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 150 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

150

Planned (sponsor's estimate)

Start

Jan 5, 2026

Primary completion

Sep 2027

Study completion Oct 2027

Sponsor

Lead sponsor
Navigator Medicines, Inc.Industry
Sponsor type
Industry
First posted
Feb 3, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The main objective of this study is to determine if NAV-240 works more effectively than a dummy treatment (placebo) for participants with moderate-to-severe HS. The main endpoint of this study is the percentage of participants achieving Hidradenitis Suppurativa Clinical Response (HiSCR) 75 at Week 16, meaning at least a 75% reduction in inflamed skin bumps (abscess and inflammatory nodule (AN) count) with no increase in number of abscesses or draining tunnels (channels under the skin that leak fluid or pus) compared to the baseline (start of the study). Participants will: * Receive NAV-240 dose 1, NAV-240 dose 2 or placebo as a drip into the veins (intravenous infusion). * Visit the clinic up to 9 times for checkups and tests over 22 weeks. * Complete a daily diary about their skin pain.

Conditions

  • Hidradenitis Suppurativa (HS)

Interventions

  • NAV-240Drug

    NAV-240 for Intravenous Infusion

  • Placebo to match NAV-240Drug

    Placebo to match NAV-240 for Intravenous Infusion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Proportion of participants achieving Hidradenitis Suppurativa Clinical Response (HiSCR) 75Time frame: Baseline to Week 16

Locations

41 sites in 8 countries. Site status is shown where the registry gives one.

  • Medical Dermatology Specialist

    Phoenix, Arizona · Recruiting

  • Scottsdale Clinical Trials

    Scottsdale, Arizona · Recruiting

  • Accel Research Sites Network

    Maitland, Florida · Recruiting

  • Floridian Research Institute

    Miami, Florida · Recruiting

  • Cordova Research Institute

    Miami, Florida · Recruiting

  • Ziaderm Research, LLC

    North Miami Beach, Florida · Recruiting

  • FWD Clinical Research

    Tamarac, Florida · Recruiting

  • MplusM - D&H Tamarac Research Center

    Tamarac, Florida · Recruiting

  • ForCare Clinical Research

    Tampa, Florida · Recruiting

  • Kentucky Advanced Medical Research LLC

    Murray, Kentucky · Recruiting

  • Beth Israel Deaconess Medical Center

    Boston, Massachusetts · Recruiting

  • SKY Integrative Medical Center

    Ridgeland, Mississippi · Recruiting

  • StracSkin, PLLC

    Portsmouth, New Hampshire · Recruiting

  • Equity Medical, LLC

    The Bronx, New York · Recruiting

  • Medical Center Medconsult Pleven

    Lovech, Bulgaria · Recruiting

  • MC Medconsult Pleven

    Pleven, Bulgaria · Recruiting

  • Ambulatory for Specialized Medical Help - skin and venereal diseases

    Sofia, Bulgaria · Recruiting

  • Diagnostic Consultative Center Fokus-5 Medical Establishment for Outpatient Care EOOD

    Sofia, Bulgaria · Recruiting

  • FACET Dermatology

    Toronto, Ontario, Canada · Recruiting

  • Research Toronto

    Toronto, Ontario, Canada · Recruiting

  • Centre de Recherche Saint-Louis (Quebec)

    Montreal, Quebec, Canada · Recruiting

  • LTD Aversi Clinic - Dermatology

    Tbilisi, Georgia · Recruiting

  • LTD Israel-Georgian Medical Research Clinic Healthycore

    Tbilisi, Georgia · Recruiting

  • LTD MediClub Georgia

    Tbilisi, Georgia · Recruiting

  • LTD Multiprofile Clinic Consilium Medulla

    Tbilisi, Georgia · Not yet recruiting

  • St. Josef Hospital Bochum - Dermatologie, Venerologie und Allergologie

    Bochum, Germany · Recruiting

  • J. W. Goethe Universitaet Frankfurt Zentrum f. Dermatologie

    Frankfurt, Germany · Recruiting

  • Universitaetsklinikum Schleswig-Holstein (UKSH) - Campus Kiel - Klinik fuer Dermatologie, Venerologie und Allergologie

    Kiel, Germany · Recruiting

  • Universitaetsklinikum Schleswig-Holstein (UKSH) - Campus Luebeck

    Lübeck, Germany · Recruiting

  • BAG Dres. med. Quist PartG

    Mainz, Germany · Recruiting

  • Debreceni Egyetem Klinikai Központ - Dermatology

    Debrecen, Hungary · Recruiting

  • Pécsi Tudományegyetem Klinikai Központ - Bőr-, Nemikórtani és Onkoderma

    Pécs, Hungary · Recruiting

  • Holsamed

    Katowice, Poland · Recruiting

  • Dermedic Jacek Zdybski

    Kielce, Poland · Recruiting

  • Labderm Essence

    Ossy, Poland · Recruiting

  • Klinika Ambroziak Dermatologia

    Warsaw, Poland · Recruiting

  • OT CO Zdrowie

    Warsaw, Poland · Recruiting

  • Centrum Columbus

    Wroclaw, Poland · Recruiting

  • Futuremeds Romania - Brasov - Dermatology

    Brasov, Romania · Recruiting

  • Spitalul Clinic Colentina - Dermatology II

    Bucharest, Romania · Recruiting

Showing 40 of 41 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.